JP7551496B2 - 全身送達のためのプラットフォーム腫瘍溶解性ベクター - Google Patents
全身送達のためのプラットフォーム腫瘍溶解性ベクター Download PDFInfo
- Publication number
- JP7551496B2 JP7551496B2 JP2020544346A JP2020544346A JP7551496B2 JP 7551496 B2 JP7551496 B2 JP 7551496B2 JP 2020544346 A JP2020544346 A JP 2020544346A JP 2020544346 A JP2020544346 A JP 2020544346A JP 7551496 B2 JP7551496 B2 JP 7551496B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- nucleic acid
- oncolytic
- exogenous nucleic
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012385 systemic delivery Methods 0.000 title claims description 30
- 230000000174 oncolytic effect Effects 0.000 title description 220
- 239000013598 vector Substances 0.000 title description 26
- 244000309459 oncolytic virus Species 0.000 claims description 372
- 150000007523 nucleic acids Chemical class 0.000 claims description 331
- 102000039446 nucleic acids Human genes 0.000 claims description 323
- 108020004707 nucleic acids Proteins 0.000 claims description 323
- 241000700618 Vaccinia virus Species 0.000 claims description 315
- 206010028980 Neoplasm Diseases 0.000 claims description 312
- 241000700605 Viruses Species 0.000 claims description 190
- 238000012217 deletion Methods 0.000 claims description 149
- 230000037430 deletion Effects 0.000 claims description 149
- 230000035772 mutation Effects 0.000 claims description 114
- 239000012634 fragment Substances 0.000 claims description 89
- 230000004048 modification Effects 0.000 claims description 84
- 238000012986 modification Methods 0.000 claims description 84
- 230000003612 virological effect Effects 0.000 claims description 76
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 75
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 75
- 101150108168 A33R gene Proteins 0.000 claims description 68
- 102000009410 Chemokine receptor Human genes 0.000 claims description 64
- 108050000299 Chemokine receptor Proteins 0.000 claims description 64
- 108700005077 Viral Genes Proteins 0.000 claims description 39
- 101150039990 B13R gene Proteins 0.000 claims description 34
- 101150023320 B16R gene Proteins 0.000 claims description 34
- 101100232885 Cowpox virus (strain Brighton Red) CPXV209 gene Proteins 0.000 claims description 34
- 101150073066 F13L gene Proteins 0.000 claims description 34
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 claims description 34
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 claims description 34
- 101000836070 Rattus norvegicus Serine protease inhibitor A3L Proteins 0.000 claims description 34
- 101710142113 Serine protease inhibitor A3K Proteins 0.000 claims description 34
- 102100027654 Transcription factor PU.1 Human genes 0.000 claims description 34
- 101100004091 Vaccinia virus (strain Copenhagen) B15R gene Proteins 0.000 claims description 34
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 claims description 34
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 claims description 34
- 101100340726 Vaccinia virus (strain Western Reserve) VACWR197 gene Proteins 0.000 claims description 34
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 claims description 34
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 claims description 34
- 102000019034 Chemokines Human genes 0.000 claims description 30
- 108010012236 Chemokines Proteins 0.000 claims description 30
- 230000010076 replication Effects 0.000 claims description 30
- 108020004440 Thymidine kinase Proteins 0.000 claims description 27
- 238000012384 transportation and delivery Methods 0.000 claims description 22
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 241000700584 Simplexvirus Species 0.000 claims description 12
- 101150101278 A52R gene Proteins 0.000 claims description 10
- 102000003675 cytokine receptors Human genes 0.000 claims description 9
- 108010057085 cytokine receptors Proteins 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 8
- 241000710185 Mengo virus Species 0.000 claims description 8
- 241000702263 Reovirus sp. Species 0.000 claims description 8
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 241000700562 Myxoma virus Species 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 description 151
- 239000008194 pharmaceutical composition Substances 0.000 description 143
- 201000011510 cancer Diseases 0.000 description 132
- 238000000034 method Methods 0.000 description 113
- 102000001974 Hyaluronidases Human genes 0.000 description 110
- 108010003272 Hyaluronate lyase Proteins 0.000 description 106
- 229960002773 hyaluronidase Drugs 0.000 description 100
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 64
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 64
- 108090000623 proteins and genes Proteins 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 57
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 55
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 43
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 42
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 42
- 102000003812 Interleukin-15 Human genes 0.000 description 41
- 108090000172 Interleukin-15 Proteins 0.000 description 41
- 101150003725 TK gene Proteins 0.000 description 41
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 37
- 102000013818 Fractalkine Human genes 0.000 description 37
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 36
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 description 36
- 101150049392 A34R gene Proteins 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 35
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 34
- 102100030837 E3 SUMO-protein ligase PIAS3 Human genes 0.000 description 34
- 108700010013 HMGB1 Proteins 0.000 description 34
- 101150021904 HMGB1 gene Proteins 0.000 description 34
- 102100037907 High mobility group protein B1 Human genes 0.000 description 34
- 101000583444 Homo sapiens E3 SUMO-protein ligase PIAS3 Proteins 0.000 description 34
- 101150115056 A31R gene Proteins 0.000 description 33
- 101150076005 A36R gene Proteins 0.000 description 33
- 101150045588 A38L gene Proteins 0.000 description 33
- 101150091700 A41L gene Proteins 0.000 description 33
- 101150091263 E3L gene Proteins 0.000 description 33
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 description 33
- 101150096427 I3L gene Proteins 0.000 description 33
- 101150035509 N1L gene Proteins 0.000 description 33
- 101150073111 NPH1 gene Proteins 0.000 description 33
- 101800003344 Vaccinia growth factor Proteins 0.000 description 33
- 101100272150 Vaccinia virus (strain Copenhagen) B8R gene Proteins 0.000 description 33
- 101100287474 Vaccinia virus (strain Copenhagen) K3L gene Proteins 0.000 description 33
- 101100459380 Vaccinia virus (strain Western Reserve) VACWR028 gene Proteins 0.000 description 33
- 101100287475 Vaccinia virus (strain Western Reserve) VACWR034 gene Proteins 0.000 description 33
- 101100332586 Vaccinia virus (strain Western Reserve) VACWR059 gene Proteins 0.000 description 33
- 101100054204 Vaccinia virus (strain Western Reserve) VACWR156 gene Proteins 0.000 description 33
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 description 33
- 101100000236 Vaccinia virus (strain Western Reserve) VACWR159 gene Proteins 0.000 description 33
- 101100107503 Vaccinia virus (strain Western Reserve) VACWR166 gene Proteins 0.000 description 33
- 101100272151 Vaccinia virus (strain Western Reserve) VACWR190 gene Proteins 0.000 description 33
- 101800001863 Variola growth factor Proteins 0.000 description 33
- 102220553839 Cyclic GMP-AMP synthase_K7R_mutation Human genes 0.000 description 31
- 101100453330 Vaccinia virus (strain Copenhagen) K7R gene Proteins 0.000 description 31
- 101100453331 Vaccinia virus (strain Western Reserve) VACWR039 gene Proteins 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 230000001225 therapeutic effect Effects 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 210000004881 tumor cell Anatomy 0.000 description 25
- 102220468893 Peptidyl-tRNA hydrolase ICT1, mitochondrial_A52R_mutation Human genes 0.000 description 24
- 101100321860 Vaccinia virus (strain Copenhagen) A52R gene Proteins 0.000 description 24
- 101100321861 Vaccinia virus (strain Western Reserve) VACWR178 gene Proteins 0.000 description 24
- 101100161331 Variola virus (isolate Human/India/Ind3/1967) A46R gene Proteins 0.000 description 24
- 238000011374 additional therapy Methods 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- 229940090044 injection Drugs 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 230000002601 intratumoral effect Effects 0.000 description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 20
- 239000002552 dosage form Substances 0.000 description 20
- 229920002674 hyaluronan Polymers 0.000 description 20
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 19
- 229940099552 hyaluronan Drugs 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 19
- 239000000651 prodrug Substances 0.000 description 19
- 210000004962 mammalian cell Anatomy 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 101100388335 Raccoon poxvirus VH1 gene Proteins 0.000 description 17
- 230000000593 degrading effect Effects 0.000 description 17
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- 230000000813 microbial effect Effects 0.000 description 17
- 108060001084 Luciferase Proteins 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 238000007911 parenteral administration Methods 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 238000011725 BALB/c mouse Methods 0.000 description 14
- 102000006601 Thymidine Kinase Human genes 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 13
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 13
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 13
- 101100497626 Mus musculus Cxcr4 gene Proteins 0.000 description 13
- 102100030411 Neutrophil collagenase Human genes 0.000 description 13
- 238000007910 systemic administration Methods 0.000 description 13
- 206010025323 Lymphomas Diseases 0.000 description 12
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- -1 LIGHT Proteins 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 230000029812 viral genome replication Effects 0.000 description 11
- 108050009363 Hyaluronidases Proteins 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 230000000973 chemotherapeutic effect Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 238000010253 intravenous injection Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 9
- 101150105073 SCR1 gene Proteins 0.000 description 9
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229960005277 gemcitabine Drugs 0.000 description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 8
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 238000003306 harvesting Methods 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000005415 bioluminescence Methods 0.000 description 7
- 230000029918 bioluminescence Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 108010048296 hyaluronidase PH-20 Proteins 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 6
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 6
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 101100495162 Mus musculus Ccr5 gene Proteins 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000008297 liquid dosage form Substances 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 101150066719 VH1 gene Proteins 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 4
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 4
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 4
- 101150020958 K7R gene Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000012338 Therapeutic targeting Methods 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 4
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 241000877350 Alphaentomopoxvirus Species 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 3
- 241000700663 Avipoxvirus Species 0.000 description 3
- 241000700576 Betaentomopoxvirus Species 0.000 description 3
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 3
- 108091008927 CC chemokine receptors Proteins 0.000 description 3
- 102000005674 CCR Receptors Human genes 0.000 description 3
- 108091008925 CX3C chemokine receptors Proteins 0.000 description 3
- 108091008928 CXC chemokine receptors Proteins 0.000 description 3
- 102000054900 CXCR Receptors Human genes 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000700664 Capripoxvirus Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 3
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 3
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 3
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 3
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 3
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 241000700563 Leporipoxvirus Species 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 241000700639 Parapoxvirus Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 3
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 description 3
- 101150055528 SPAM1 gene Proteins 0.000 description 3
- 241001632234 Senecavirus Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 241000700568 Suipoxvirus Species 0.000 description 3
- 241000700574 Yatapoxvirus Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010061825 Duodenal neoplasm Diseases 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 241000545744 Hirudinea Species 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 2
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 2
- 102100024130 Matrix metalloproteinase-23 Human genes 0.000 description 2
- 102100024131 Matrix metalloproteinase-25 Human genes 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010054184 Small intestine carcinoma Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000000312 duodenum cancer Diseases 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000012379 oncolytic virotherapy Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 2
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- KNVZXMUMZXUMLE-VWURTLBMSA-N (2s)-2-amino-3-(4-phosphonooxyphenyl)propanoic acid;(2s)-2-amino-3-phosphonooxypropanoic acid Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O.OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 KNVZXMUMZXUMLE-VWURTLBMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 241000607620 Aliivibrio fischeri Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000604931 Bdellovibrio bacteriovorus Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 101150049756 CCL6 gene Proteins 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 241000543397 Crocodylidpoxvirus Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000256867 Dolichovespula arenaria Species 0.000 description 1
- 241000256868 Dolichovespula maculata Species 0.000 description 1
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 1
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 1
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 description 1
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 1
- 101001041128 Homo sapiens Hyaluronidase-3 Proteins 0.000 description 1
- 101001041120 Homo sapiens Hyaluronidase-4 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
- 101001011884 Homo sapiens Matrix metalloproteinase-15 Proteins 0.000 description 1
- 101001011887 Homo sapiens Matrix metalloproteinase-17 Proteins 0.000 description 1
- 101001013139 Homo sapiens Matrix metalloproteinase-20 Proteins 0.000 description 1
- 101001013142 Homo sapiens Matrix metalloproteinase-21 Proteins 0.000 description 1
- 101000627851 Homo sapiens Matrix metalloproteinase-23 Proteins 0.000 description 1
- 101000627858 Homo sapiens Matrix metalloproteinase-24 Proteins 0.000 description 1
- 101000627852 Homo sapiens Matrix metalloproteinase-25 Proteins 0.000 description 1
- 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 1
- 101000627860 Homo sapiens Matrix metalloproteinase-27 Proteins 0.000 description 1
- 101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 description 1
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- 102100021081 Hyaluronidase-4 Human genes 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 241000593474 Loxosceles intermedia Species 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 108091007144 MMP23A Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
- 102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 1
- 102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 1
- 102100024132 Matrix metalloproteinase-27 Human genes 0.000 description 1
- 102100026799 Matrix metalloproteinase-28 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001052688 Streptomyces koganeiensis Species 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 102000046319 human OGA Human genes 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023222848A JP2024019723A (ja) | 2017-10-31 | 2023-12-28 | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579517P | 2017-10-31 | 2017-10-31 | |
| US62/579,517 | 2017-10-31 | ||
| PCT/US2018/058456 WO2019089755A1 (en) | 2017-10-31 | 2018-10-31 | Platform oncolytic vector for systemic delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222848A Division JP2024019723A (ja) | 2017-10-31 | 2023-12-28 | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021500932A JP2021500932A (ja) | 2021-01-14 |
| JP2021500932A5 JP2021500932A5 (enExample) | 2021-12-09 |
| JPWO2019089755A5 JPWO2019089755A5 (enExample) | 2023-02-24 |
| JP7551496B2 true JP7551496B2 (ja) | 2024-09-17 |
Family
ID=66333632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544346A Active JP7551496B2 (ja) | 2017-10-31 | 2018-10-31 | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| JP2023222848A Pending JP2024019723A (ja) | 2017-10-31 | 2023-12-28 | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222848A Pending JP2024019723A (ja) | 2017-10-31 | 2023-12-28 | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US12036257B2 (enExample) |
| EP (2) | EP3973973A1 (enExample) |
| JP (2) | JP7551496B2 (enExample) |
| KR (1) | KR20200081438A (enExample) |
| CN (1) | CN111556757A (enExample) |
| AU (1) | AU2018359420A1 (enExample) |
| CA (1) | CA3081436A1 (enExample) |
| WO (1) | WO2019089755A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| JP7312412B2 (ja) | 2018-01-05 | 2023-07-21 | オタワ ホスピタル リサーチ インスティチュート | 改変オルトポックスウイルスベクター |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| CN111154806A (zh) * | 2020-01-08 | 2020-05-15 | 深圳普菲科生命科技有限公司 | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 |
| BR112022013521A2 (pt) * | 2020-01-09 | 2022-09-13 | Pfizer | Vírus vaccinia recombinante |
| EP4097475A4 (en) * | 2020-01-29 | 2024-05-22 | Helix Nanotechnologies, Inc. | METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION OF NF-KB PATHWAYS AND/OR IRF PATHWAYS |
| US20220033784A1 (en) * | 2020-07-14 | 2022-02-03 | Pfizer Inc. | Recombinant vaccinia virus |
| WO2022109133A1 (en) * | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2022170919A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京惟亚德生物医药有限公司 | 一种重组溶瘤腺病毒及其应用 |
| CN113144181B (zh) * | 2021-04-20 | 2022-07-19 | 徐州医科大学 | 一种靶向b7h3的dna疫苗、制备方法及应用 |
| WO2022232375A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| EP4604982A2 (en) * | 2022-10-19 | 2025-08-27 | KaliVir Immunotherapeutics, Inc. | Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof |
| CN116947981B (zh) * | 2023-07-07 | 2024-04-23 | 华中农业大学 | 一种lsdv和gtpv通用型诊断抗原及其单克隆抗体和应用 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016224A1 (en) | 2006-08-25 | 2010-01-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe | Compositions and methods for modulating an immune response |
| WO2017043815A1 (en) | 2015-09-08 | 2017-03-16 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4409450A (en) | 1982-07-29 | 1983-10-11 | Amp Incorporated | Double pole membrane switch having preferred sequence closing feature |
| IL71275A0 (en) | 1983-03-21 | 1984-06-29 | Sparamedica Ag | Human interleukin-2-and its preparation |
| FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5352806A (en) | 1992-04-17 | 1994-10-04 | Abbott Laboratories | Taxol derivatives |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
| KR100648536B1 (ko) | 1997-11-10 | 2006-11-24 | 셀러지 파마세우티칼스, 인크 | 침투 보강 및 자극 감소를 위한 계 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AT406376B (de) | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
| JPH11268865A (ja) | 1998-03-20 | 1999-10-05 | Omron Corp | 用紙仕分け装置及び方法 |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6198323B1 (en) | 1999-01-28 | 2001-03-06 | Lucent Technologies Inc. | Flip-flop having gated inverter feedback structure with embedded preset/clear logic |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| CO5280224A1 (es) | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
| NZ521270A (en) | 2000-03-14 | 2003-06-30 | Bavarian Nordic As | Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| DK1276501T5 (da) | 2000-04-25 | 2007-02-26 | Immunex Corp | Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi |
| US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| WO2001091802A1 (en) | 2000-05-30 | 2001-12-06 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| US7030099B2 (en) | 2000-07-21 | 2006-04-18 | Research Corporation Technologies, Inc. | Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells |
| CA2424216A1 (en) | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| EP1213025A1 (de) | 2000-12-06 | 2002-06-12 | Laboratoires Serobiologiques(Societe Anonyme) | Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa |
| EP1341817A2 (en) | 2000-12-08 | 2003-09-10 | Novo Nordisk A/S | Tff peptides |
| EP1395293B1 (en) | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentiviral vectors encoding clotting factors for gene therapy |
| JP2003009883A (ja) | 2001-07-05 | 2003-01-14 | Mitsubishi Pharma Corp | マスト細胞の細胞死誘発剤 |
| AU2002350409A1 (en) | 2001-10-26 | 2003-05-06 | Uffe Holmskov | Surfactant protein-d and atherosclerosis |
| US7368122B1 (en) | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
| AU2003258168B2 (en) | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| EP2186811A1 (en) | 2002-08-23 | 2010-05-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| GB0226251D0 (en) | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
| US20040143026A1 (en) | 2002-12-31 | 2004-07-22 | Shah Kishore R. | Bioadhesive hydrophilic composition for treatment of mammalian skin |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| SG179291A1 (en) | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP1710300A4 (en) * | 2003-12-05 | 2007-10-24 | Hokkaido Tech Licensing Office | HIGHLY SAFE POX VACCINE VIRUS AND VACCINIA VIRUS VECTOR |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| EP1838341B1 (en) * | 2005-01-20 | 2013-08-14 | Isconova AB | Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide |
| US20100094560A1 (en) | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US9133478B2 (en) | 2006-08-25 | 2015-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| GB0702695D0 (en) | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| US8003363B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| CA2963124C (en) | 2007-07-10 | 2019-10-15 | Apogenix Ag | Tnf superfamily collectin fusion proteins |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| CN106906196A (zh) * | 2008-03-06 | 2017-06-30 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| WO2010020056A1 (en) | 2008-08-21 | 2010-02-25 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| EP2184297A1 (en) | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| CA2709292A1 (en) | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
| JP5686814B2 (ja) | 2010-09-17 | 2015-03-18 | 独立行政法人科学技術振興機構 | Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法 |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| CN103429258B (zh) | 2011-01-04 | 2016-03-09 | 新罗杰公司 | 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性 |
| EP2527459A1 (en) | 2011-05-02 | 2012-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Blood-based gene detection of non-small cell lung cancer |
| JP6243333B2 (ja) | 2011-08-05 | 2017-12-06 | シラジェン バイオセラピューティクス インコーポレイテッド | ワクシニアウィルスの生成のための方法および組成物 |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014018113A1 (en) | 2012-07-24 | 2014-01-30 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| US9732325B2 (en) | 2012-09-28 | 2017-08-15 | Probiogen Ag | MVA virus and uses thereof |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| KR20140122603A (ko) | 2013-04-10 | 2014-10-20 | 신라젠(주) | 세포외 피막성 백시니아 바이러스의 생성과 관련된 단백질을 코딩하는 폴리뉴클레오티드로 형질전환된 숙주세포 |
| WO2014170389A1 (en) | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CN105705641B (zh) | 2013-07-18 | 2021-07-13 | 弗拉芒区生物技术研究所 | 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 |
| SMT202400047T1 (it) | 2013-08-22 | 2024-03-13 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapie immuno-oncolitiche |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| ME03558B (me) * | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| US20160060311A1 (en) | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Lung Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Lung Cancer Compositions Comprising the Same |
| HRP20190881T1 (hr) | 2014-08-28 | 2019-07-12 | Halozyme, Inc. | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke |
| EP3207130B1 (en) * | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| CN105829930B (zh) | 2014-10-24 | 2019-04-26 | 华为技术有限公司 | 模式复用解复用器和交换节点 |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| WO2017013419A1 (en) | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP2019528753A (ja) * | 2016-09-21 | 2019-10-17 | スティーブン エイチ． ソーン， | 高移動度グループｂｏｘｉ突然変異体 |
| WO2018058258A1 (en) | 2016-09-30 | 2018-04-05 | University Health Network | Recombinant oncolytic viruses for cancer therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| US11185586B2 (en) | 2016-11-22 | 2021-11-30 | Alloplex Biotherapeutics, Inc. | Allogeneic tumor cell vaccine |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| AU2018223211B2 (en) | 2017-02-21 | 2025-02-27 | The University Of Adelaide | T cells expressing chemokine receptors for treating cancer |
| TWI672677B (zh) | 2017-03-31 | 2019-09-21 | 鈺立微電子股份有限公司 | 用以融合多深度圖的深度圖產生裝置 |
| US20200268831A1 (en) | 2017-09-15 | 2020-08-27 | The Texas A&M University System | Methods for enhancing immunotherapy in the treatment of cancer |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| WO2019148109A1 (en) | 2018-01-26 | 2019-08-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| JP2021522784A (ja) | 2018-05-02 | 2021-09-02 | トニックス ファーマ ホールディングス リミテッド | 合成キメラワクシニアウイルス |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| AU2019377141B2 (en) | 2018-11-06 | 2024-06-06 | Calidi Biotherapeutics (Nevada), Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
| TW202038994A (zh) | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| CA3129883A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| JP7732977B2 (ja) | 2019-09-20 | 2025-09-02 | トランスジーン | Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ |
| WO2021116943A1 (en) | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| BR112022013521A2 (pt) | 2020-01-09 | 2022-09-13 | Pfizer | Vírus vaccinia recombinante |
| US20220033784A1 (en) | 2020-07-14 | 2022-02-03 | Pfizer Inc. | Recombinant vaccinia virus |
| CN112668865A (zh) | 2020-12-23 | 2021-04-16 | 贵阳市城市轨道交通集团有限公司 | 一种城市地铁风险动态分析方法 |
-
2018
- 2018-10-31 JP JP2020544346A patent/JP7551496B2/ja active Active
- 2018-10-31 EP EP21191521.0A patent/EP3973973A1/en active Pending
- 2018-10-31 AU AU2018359420A patent/AU2018359420A1/en not_active Abandoned
- 2018-10-31 WO PCT/US2018/058456 patent/WO2019089755A1/en not_active Ceased
- 2018-10-31 CN CN201880085079.9A patent/CN111556757A/zh active Pending
- 2018-10-31 EP EP18873293.7A patent/EP3703723A4/en active Pending
- 2018-10-31 KR KR1020207015355A patent/KR20200081438A/ko not_active Ceased
- 2018-10-31 US US16/759,705 patent/US12036257B2/en active Active
- 2018-10-31 CA CA3081436A patent/CA3081436A1/en active Pending
-
2021
- 2021-03-04 US US17/192,736 patent/US20210196770A1/en active Pending
- 2021-10-11 US US17/498,158 patent/US12318419B2/en active Active
- 2021-10-28 US US17/513,034 patent/US12226440B2/en active Active
-
2022
- 2022-01-14 US US17/575,787 patent/US12472217B2/en active Active
-
2023
- 2023-12-28 JP JP2023222848A patent/JP2024019723A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016224A1 (en) | 2006-08-25 | 2010-01-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe | Compositions and methods for modulating an immune response |
| WO2017043815A1 (en) | 2015-09-08 | 2017-03-16 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 義江修，ケモカイン標的療法，日本臨床免疫学会会誌，日本，2013年，36巻，4号，189-196頁 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12036257B2 (en) | 2024-07-16 |
| US20210093684A1 (en) | 2021-04-01 |
| JP2021500932A (ja) | 2021-01-14 |
| US20210196770A1 (en) | 2021-07-01 |
| CA3081436A1 (en) | 2019-05-09 |
| US12472217B2 (en) | 2025-11-18 |
| AU2018359420A1 (en) | 2020-06-04 |
| US20220054565A1 (en) | 2022-02-24 |
| US20220016192A1 (en) | 2022-01-20 |
| EP3703723A4 (en) | 2021-12-15 |
| WO2019089755A1 (en) | 2019-05-09 |
| EP3973973A1 (en) | 2022-03-30 |
| US12226440B2 (en) | 2025-02-18 |
| US12318419B2 (en) | 2025-06-03 |
| EP3703723A1 (en) | 2020-09-09 |
| US20220125865A1 (en) | 2022-04-28 |
| KR20200081438A (ko) | 2020-07-07 |
| CN111556757A (zh) | 2020-08-18 |
| JP2024019723A (ja) | 2024-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551496B2 (ja) | 全身送達のためのプラットフォーム腫瘍溶解性ベクター | |
| AU2022200169B2 (en) | High mobility group box i mutant | |
| KR102619496B1 (ko) | Stat3를 타겟으로 하는 종양용해성 바이러스 | |
| US20250249054A1 (en) | Methods of Treating Cancer | |
| JP7625589B2 (ja) | 改変細胞外エンベロープウイルス | |
| WO2019046619A1 (en) | TP53 GENE AS A BIOMARKER FOR REACTIVITY TO IMMUNOTHERAPY | |
| HK40058302A (en) | Methods of treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211027 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211027 |
|
| AA91 | Notification that invitation to amend document was cancelled |
Free format text: JAPANESE INTERMEDIATE CODE: A971091 Effective date: 20230228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240612 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240704 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240808 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240904 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7551496 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |